Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:D-galactopyranose
go back to main search page
Accession:CHEBI:4139 term browser browse the term
Definition:A galactopyranose having D-configuration.
Synonyms:related_synonym: D-Galactose;   Formula=C6H12O6;   InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1;   InChIKey=WQZGKKKJIJFFOK-SVZMEOIVSA-N;   SMILES=OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O;   WURCS=2.0/1,1,0/[a2112h-1x_1-5]/1/
 xref: CAS:10257-28-0;   CAS:59-23-4;   GlyGen:G68158BT;   GlyTouCan:G68158BT;   Gmelin:83257;   KEGG:C00124;   KNApSAcK:C00019681;   PMID:1378088;   PMID:17336832;   PMID:19913595;   PMID:28709133;   Reaxys:1281605;   Wikipedia:Galactose


show annotations for term's descendants           Sort by:
1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cxcl10 C-X-C motif chemokine ligand 10 increases expression ISO KRN 7000 results in increased expression of CXCL10 protein CTD PMID:15867097 NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975 		JBrowse link
G Il12b interleukin 12B increases expression ISO KRN 7000 results in increased expression of IL12B protein CTD PMID:15867097 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
2-amino-2-deoxy-D-galactopyranose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases activity
multiple interactions 		EXP Galactosamine results in increased activity of ACHE protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of ACHE protein] 		CTD PMID:35673974 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Acta2 actin alpha 2, smooth muscle increases expression
multiple interactions 		EXP Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein] 		CTD PMID:27836788 PMID:27876602 NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Actb actin, beta increases expression EXP Galactosamine results in increased expression of ACTB mRNA CTD PMID:22563491 NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877 		JBrowse link
G Afp alpha-fetoprotein increases expression EXP Galactosamine results in increased expression of AFP protein CTD PMID:61145 PMID:16965562 NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein] CTD PMID:37934488 NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Alb albumin multiple interactions
decreases expression
increases expression 		EXP [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased expression of ALB protein]
Galactosamine results in decreased expression of ALB protein
Galactosamine results in increased expression of ALB mRNA 		CTD PMID:17963606 PMID:18779383 PMID:22310181 PMID:35838105 NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836 		JBrowse link
G Ambp alpha-1-microglobulin/bikunin precursor increases expression EXP Galactosamine results in increased expression of AMBP mRNA CTD PMID:18779383 NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331 		JBrowse link
G Apoe apolipoprotein E decreases expression EXP Galactosamine results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein CTD PMID:28844859 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atm ATM serine/threonine kinase increases expression
multiple interactions 		EXP Galactosamine results in increased expression of ATM protein
glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein] 		CTD PMID:24565947 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		ISO
EXP 		2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]
Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA] 		CTD PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 More... NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO
EXP 		2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein; [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]
glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein]
Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein 		CTD PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 PMID:37934488 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein CTD PMID:12907702 PMID:21401295 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Casp1 caspase 1 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] CTD PMID:32453893 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
increases activity 		ISO
EXP 		2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein
2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein] 		CTD PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] CTD PMID:21146893 NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] CTD PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression 		ISO
EXP 		3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein] 		CTD PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 Ensembl chr 5:154,109,046...154,126,626 JBrowse link
G Cat catalase multiple interactions
increases activity
decreases activity 		ISO
EXP 		6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]]
Galactosamine results in increased activity of CAT protein
Galactosamine results in decreased activity of CAT protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of CAT protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of CAT protein] 		CTD PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 More... NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]] CTD PMID:21146893 PMID:25200604 PMID:28887131 PMID:35691465 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] CTD PMID:21146893 NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] CTD PMID:22107987 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] CTD PMID:20850421 NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases phosphorylation
multiple interactions 		EXP Galactosamine results in increased phosphorylation of CHUK protein
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein] 		CTD PMID:22310181 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065 		JBrowse link
G Col1a1 collagen type I alpha 1 chain increases expression
multiple interactions 		EXP Galactosamine results in increased expression of COL1A1 mRNA
Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA] 		CTD PMID:27876602 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions
increases expression 		EXP Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA] CTD PMID:27876602 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A multiple interactions
decreases expression 		ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] CTD PMID:17936189 NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein CTD PMID:15576625 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein CTD PMID:15576625 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] CTD PMID:28887131 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] CTD PMID:20558151 PMID:20850421 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases expression EXP Galactosamine results in decreased expression of CYP1A2 protein CTD PMID:16208626 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases expression
multiple interactions 		EXP Galactosamine results in decreased expression of CYP2E1 protein
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of CYP2E1 protein] 		CTD PMID:16208626 PMID:35838105 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases expression
multiple interactions 		ISO Galactosamine results in decreased expression of CYP3A4 mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] 		CTD PMID:17936189 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA CTD PMID:28844859 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of EGFR protein] CTD PMID:36414212 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions EXP 4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA CTD PMID:28844859 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of G6PD protein] CTD PMID:35838105 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLC mRNA] CTD PMID:35691465 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GCLM mRNA] CTD PMID:28887131 PMID:35691465 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gdf11 growth differentiation factor 11 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BAX protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of BCL2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GDF11 protein; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the cleavage of CASP3 protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BAX protein]; GDF11 protein affects the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of BCL2 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of AKT1 protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] CTD PMID:37934488 NCBI chr 7:1,311,732...1,325,211
Ensembl chr 7:1,311,732...1,320,725 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases expression 		EXP
ISO 		4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of GPT protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of GPT protein]
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein] 		CTD PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 More... NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions
decreases activity 		EXP [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in decreased activity of GSR protein]; Vitamin U inhibits the reaction [Galactosamine results in decreased activity of GSR protein] CTD PMID:35673974 PMID:35838105 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstt3 glutathione S-transferase, theta 3 affects response to substance EXP GSTT3 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr20:12,875,184...12,882,540
Ensembl chr20:12,874,854...12,882,599 		JBrowse link
G H3f4 H3.4 histone, cluster member increases expression EXP Galactosamine results in increased expression of H3F4 mRNA CTD PMID:11779202 NCBI chr10:43,740,702...43,741,262 JBrowse link
G Habp2 hyaluronan binding protein 2 increases activity ISO Galactosamine results in increased activity of HABP2 protein CTD PMID:11510480 NCBI chr 1:255,315,870...255,350,161
Ensembl chr 1:255,315,915...255,350,160 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] CTD PMID:28887131 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein CTD PMID:28844859 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression 		ISO
EXP 		8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein; Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]
Galactosamine results in decreased expression of HMOX1 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; purpurin anthraquinone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of HMOX1 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA] 		CTD PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 PMID:35691465 More... NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hp haptoglobin multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HP protein] CTD PMID:36414212 NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein CTD PMID:28844859 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA 		CTD PMID:16431966 PMID:25200604 NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Ifng interferon gamma multiple interactions
increases expression 		ISO
EXP 		[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA] 		CTD PMID:15486963 PMID:22310181 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression EXP Galactosamine results in increased expression of IGFBP1 mRNA CTD PMID:11779202 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
increases phosphorylation 		EXP mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] CTD PMID:22310181 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250 		JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression 		ISO
EXP 		[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]
Galactosamine results in decreased expression of IL10 mRNA
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA] 		CTD PMID:15486963 PMID:17963606 PMID:22310181 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il12b interleukin 12B multiple interactions
increases expression 		ISO
EXP 		[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA] 		CTD PMID:19913045 PMID:22310181 NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903 		JBrowse link
G Il18 interleukin 18 increases expression
multiple interactions 		ISO
EXP 		Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein
mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein] 		CTD PMID:19913045 PMID:20102673 PMID:22310181 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression 		EXP
ISO 		Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]] 		CTD PMID:15135310 PMID:22310181 PMID:25620059 PMID:28125915 PMID:28887131 More... NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression 		ISO
EXP 		3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]
Galactosamine results in increased expression of IL6 mRNA
[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of IL6 protein] 		CTD PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions ISO 8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased degradation of KEAP1 protein] CTD PMID:35691465 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Lcat lecithin cholesterol acyltransferase decreases activity EXP Galactosamine results in decreased activity of LCAT protein CTD PMID:6631239 NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231 		JBrowse link
G Lep leptin multiple interactions
increases response to substance 		ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262 		JBrowse link
G Lepr leptin receptor multiple interactions
increases response to substance 		ISO [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation 		ISO
EXP 		[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein] 		CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation 		ISO
EXP 		[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]
Galactosamine results in increased phosphorylation of MAPK3 protein
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein] 		CTD PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Maz MYC associated zinc finger protein multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of MAZ protein] CTD PMID:36414212 NCBI chr 1:191,060,271...191,065,722
Ensembl chr 1:181,629,729...181,650,408 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions EXP
ISO 		4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA 		CTD PMID:28844859 PMID:28887131 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Mgst1 microsomal glutathione S-transferase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein; Dithiothreitol inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of MGST1 protein] CTD PMID:18634816 NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892 		JBrowse link
G Mir34c microRNA 34c multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MIR34C mRNA] CTD PMID:36414212 NCBI chr 8:51,409,726...51,409,802
Ensembl chr 8:51,409,726...51,409,802 		JBrowse link
G Mpo myeloperoxidase multiple interactions
increases activity 		ISO
EXP 		(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein]
Galactosamine results in increased activity of MPO protein
[Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein]; Vitamin U inhibits the reaction [Galactosamine results in increased activity of MPO protein] 		CTD PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 PMID:35673974 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of MTOR protein] CTD PMID:37934488 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Ndufb6 NADH:ubiquinone oxidoreductase subunit B6 multiple interactions
decreases expression 		ISO Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] CTD PMID:19523936 NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects localization
increases activity
multiple interactions
decreases expression 		EXP
ISO 		Galactosamine affects the localization of NFE2L2 protein
Galactosamine results in increased activity of NFE2L2 protein
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]
mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein] 		CTD PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] CTD PMID:17936189 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases expression 		EXP
ISO 		Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein] 		CTD PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions ISO [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] CTD PMID:32453893 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression 		ISO
EXP 		[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]
Galactosamine results in increased expression of NOS2 mRNA
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]
Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein
[[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA] 		CTD PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 More... NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 decreases expression
multiple interactions 		EXP
ISO 		Galactosamine results in decreased expression of NQO1 protein
8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NQO1 protein]
mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein] 		CTD PMID:22310181 PMID:28887131 PMID:35691465 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Ocln occludin multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of OCLN protein] CTD PMID:36414212 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] CTD PMID:20558151 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3r1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein]]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein; GDF11 protein affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased phosphorylation of PIK3R1 protein] CTD PMID:37934488 NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631 		JBrowse link
G Ppara peroxisome proliferator activated receptor alpha increases expression
multiple interactions
increases activity
decreases expression 		ISO Galactosamine results in increased expression of PPARA mRNA
[Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein
Galactosamine results in increased activity of PPARA protein
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA] 		CTD PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346 		JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] CTD PMID:30236599 PMID:30550845 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468 		JBrowse link
G Ppia peptidylprolyl isomerase A decreases expression EXP Galactosamine results in decreased expression of CYCA mRNA CTD PMID:22563491 NCBI chr14:81,279,292...81,282,960
Ensembl chr14:81,275,091...81,299,601 		JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] CTD PMID:22107987 NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression 		ISO
EXP 		[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein]
Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein] 		CTD PMID:22107987 PMID:25620059 PMID:32453893 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptn pleiotrophin increases expression EXP Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein CTD PMID:12057922 NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin affects response to substance EXP PTTG1 mRNA affects the susceptibility to Galactosamine CTD PMID:19800905 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
increases expression 		ISO
EXP 		[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]
mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein] 		CTD PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Sdc3 syndecan 3 increases expression EXP Galactosamine results in increased expression of SDC3 mRNA CTD PMID:12057922 NCBI chr 5:142,965,659...142,998,390
Ensembl chr 5:142,965,591...142,996,480 		JBrowse link
G Serpine1 serpin family E member 1 increases expression EXP Galactosamine results in increased expression of SERPINE1 mRNA CTD PMID:11779202 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Sesn2 sestrin 2 multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein CTD PMID:25637945 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260 		JBrowse link
G Smad2 SMAD family member 2 multiple interactions
increases phosphorylation 		EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein] CTD PMID:27876602 NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323 		JBrowse link
G Smad3 SMAD family member 3 multiple interactions
increases phosphorylation 		EXP Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein] CTD PMID:27876602 NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960 		JBrowse link
G Smad7 SMAD family member 7 multiple interactions
decreases expression 		EXP Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein] CTD PMID:27876602 NCBI chr18:71,263,508...71,291,849
Ensembl chr18:68,988,429...69,016,765 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA CTD PMID:21401295 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sord sorbitol dehydrogenase multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] CTD PMID:30822415 NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] CTD PMID:19913045 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] CTD PMID:28887131 NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stat5b signal transducer and activator of transcription 5B decreases activity ISO Galactosamine results in decreased activity of STAT5B protein CTD PMID:30114225 NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions 		EXP Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein
Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein] 		CTD PMID:27836788 PMID:27876602 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tjp1 tight junction protein 1 multiple interactions EXP [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA; [Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; Lactulose inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 mRNA]; qingdu inhibits the reaction [[Thioacetamide co-treated with Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of TJP1 protein] CTD PMID:36414212 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] CTD PMID:28125915 PMID:32453893 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression 		ISO
EXP 		1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA]; 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; 8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; [TNF protein co-treated with Galactosamine] results in increased expression of CCL2 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of ICAM1 mRNA; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nilotinib inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]
Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein
[Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein]
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein] 		CTD PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] CTD PMID:28213090 NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:87,963,514...87,983,507 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO 1-hydroxyalantolactone inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA]; [TNF protein co-treated with Galactosamine] results in increased expression of VCAM1 mRNA CTD PMID:25200604 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA CTD PMID:28844859 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Xdh xanthine dehydrogenase increases activity
multiple interactions 		EXP Galactosamine results in increased activity of XDH protein
Vitamin U inhibits the reaction [Galactosamine results in increased activity of XDH protein] 		CTD PMID:35673974 NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] CTD PMID:20850421 NCBI chr  X:125,756,107...125,803,979
Ensembl chr  X:120,897,907...120,934,700 		JBrowse link
4-methylumbelliferyl beta-D-galactoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Car12 carbonic anhydrase 12 decreases activity ISO 4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA12 protein CTD PMID:22077347 NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440 		JBrowse link
G Car9 carbonic anhydrase 9 decreases activity ISO 4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA9 protein CTD PMID:22077347 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838 		JBrowse link
alpha-D-galactose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases activity
multiple interactions 		ISO Galactose results in increased activity of ACHE protein
catalpol inhibits the reaction [Galactose results in increased activity of ACHE protein]; theaflavin-3,3'-digallate inhibits the reaction [Galactose results in increased activity of ACHE protein] 		CTD PMID:23612000 PMID:36638877 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Ager advanced glycosylation end product-specific receptor increases expression
multiple interactions
decreases expression 		ISO
EXP 		Galactose results in increased expression of AGER mRNA; Galactose results in increased expression of AGER protein
agomelatine inhibits the reaction [Galactose results in increased expression of AGER protein]
[Ethanol co-treated with Galactose] results in decreased expression of AGER protein
Galactose results in decreased expression of AGER protein 		CTD PMID:22687555 PMID:33516661 PMID:34673010 NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078 		JBrowse link
G Aif1 allograft inflammatory factor 1 increases expression
multiple interactions 		ISO
EXP 		Galactose results in increased expression of AIF1 protein
agomelatine inhibits the reaction [Galactose results in increased expression of AIF1 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of AIF1 protein]
lycopene inhibits the reaction [Galactose results in increased expression of AIF1 protein] 		CTD PMID:28974442 PMID:34673010 NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 multiple interactions
increases expression 		ISO protocatechuic acid inhibits the reaction [Galactose results in increased expression of AKR1B1 mRNA] CTD PMID:22687555 NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Aox1 aldehyde oxidase 1 increases expression
multiple interactions 		ISO Galactose results in increased expression of AOX1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in increased expression of AOX1 mRNA] 		CTD PMID:23274001 NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770 		JBrowse link
G App amyloid beta precursor protein multiple interactions ISO [Galactose co-treated with Aluminum Chloride] results in decreased expression of APP protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of APP protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of APP protein] CTD PMID:35537655 NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561 		JBrowse link
G Aqp4 aquaporin 4 multiple interactions ISO [Ethanol co-treated with Galactose] results in decreased expression of AQP4 protein CTD PMID:33516661 NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions ISO [Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of ATF4 protein] CTD PMID:29427785 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atg5 autophagy related 5 decreases expression
multiple interactions 		EXP Galactose results in decreased expression of ATG5 mRNA
candesartan inhibits the reaction [Galactose results in decreased expression of ATG5 mRNA] 		CTD PMID:34906534 NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 decreases expression
multiple interactions 		EXP
ISO 		Galactose results in decreased expression of ATG7 protein
MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein] 		CTD PMID:28302704 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atox1 antioxidant 1 copper chaperone decreases expression
multiple interactions 		ISO Galactose results in decreased expression of ATOX1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of ATOX1 mRNA] 		CTD PMID:23274001 NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950 		JBrowse link
G Atp5f1a ATP synthase F1 subunit alpha multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein CTD PMID:25997894 NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression 		ISO
EXP 		Phycocyanin inhibits the reaction [Galactose results in increased expression of BAX protein]
agomelatine inhibits the reaction [Galactose results in increased expression of BAX protein]; Finasteride inhibits the reaction [Galactose results in increased expression of BAX protein]; Galactose promotes the reaction [sodium arsenite results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [Galactose results in increased expression of BAX protein]; Saponins inhibits the reaction [Galactose results in increased expression of BAX protein]
Galactose results in increased expression of BAX mRNA; Galactose results in increased expression of BAX protein 		CTD PMID:23036742 PMID:25892055 PMID:34673010 PMID:35259467 PMID:39265715 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression 		ISO
EXP 		Phycocyanin inhibits the reaction [Galactose results in decreased expression of BCL2 protein]
Galactose results in decreased expression of BCL2 mRNA; Galactose results in decreased expression of BCL2 protein
agomelatine inhibits the reaction [Galactose results in decreased expression of BCL2 protein]; Galactose promotes the reaction [sodium arsenite results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Galactose results in decreased expression of BCL2 protein]; Saponins inhibits the reaction [Galactose results in decreased expression of BCL2 protein] 		CTD PMID:23036742 PMID:25892055 PMID:34673010 PMID:35259467 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions 		ISO Galactose results in decreased expression of BDNF mRNA; Galactose results in decreased expression of BDNF protein
lycopene inhibits the reaction [Galactose results in decreased expression of BDNF mRNA]; lycopene inhibits the reaction [Galactose results in decreased expression of BDNF protein] 		CTD PMID:28974442 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases expression 		EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein]; candesartan inhibits the reaction [Galactose results in decreased expression of BECN1 mRNA]
Galactose results in decreased expression of BECN1 mRNA; Galactose results in decreased expression of BECN1 protein 		CTD PMID:25997894 PMID:28302704 PMID:34906534 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Casp12 caspase 12 multiple interactions
increases expression 		EXP agomelatine inhibits the reaction [Galactose results in increased expression of CASP12 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of CASP12 protein] CTD PMID:34673010 NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp3 caspase 3 increases cleavage
increases expression
multiple interactions
increases activity 		ISO
EXP 		Galactose results in increased cleavage of CASP3 protein
Galactose results in increased expression of CASP3 mRNA
Galactose results in increased expression of CASP3 protein
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of CASP3 protein]
albicanol inhibits the reaction [Galactose results in increased expression of CASP3 mRNA]; Pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein]
Phycocyanin inhibits the reaction [Galactose results in increased cleavage of CASP3 protein] 		CTD PMID:23036742 PMID:23795773 PMID:25997894 PMID:32295448 PMID:33761044 More... NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression 		EXP
ISO 		[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein]
Galactose results in increased expression of CASP9 mRNA
albicanol inhibits the reaction [Galactose results in increased expression of CASP9 mRNA]
Galactose results in increased expression of CASP9 protein 		CTD PMID:25997894 PMID:32295448 PMID:33761044 Ensembl chr 5:154,109,046...154,126,626 JBrowse link
G Cat catalase increases activity
decreases activity
affects activity
multiple interactions 		EXP
ISO 		Galactose results in increased activity of CAT protein
Galactose results in decreased activity of CAT protein
Galactose affects the activity of CAT protein
[Galactose co-treated with Aluminum Chloride] results in decreased expression of CAT protein; albicanol inhibits the reaction [Galactose results in decreased activity of CAT protein]; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of CAT protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of CAT protein]
[Galactose co-treated with Finasteride] results in increased expression of CAT mRNA; candesartan inhibits the reaction [Galactose results in decreased activity of CAT protein]; Quercetin inhibits the reaction [Galactose results in increased activity of CAT protein] 		CTD PMID:17211565 PMID:32295448 PMID:33761044 PMID:34906534 PMID:35537655 More... NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccn1 cellular communication network factor 1 multiple interactions ISO [Galactose co-treated with Fenofibrate] results in increased expression of CCN1 protein CTD PMID:39442682 NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484 		JBrowse link
G Ccn2 cellular communication network factor 2 increases expression
multiple interactions 		EXP Galactose results in increased expression of CCN2 protein
Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of CCN2 protein] 		CTD PMID:30367734 NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734 		JBrowse link
G Cdh5 cadherin 5 multiple interactions
decreases expression 		ISO Ethanol promotes the reaction [Galactose results in decreased expression of CDH5 protein] CTD PMID:33516661 NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 increases expression
multiple interactions 		ISO Galactose results in increased expression of CDK5R1 protein
gentiopicroside analog inhibits the reaction [Galactose results in increased expression of CDK5R1 protein] 		CTD PMID:36878094 NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions
increases expression 		EXP
ISO 		agomelatine inhibits the reaction [Galactose results in increased expression of CDKN2A protein]; Melatonin inhibits the reaction [Galactose results in increased expression of CDKN2A protein]
(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of CDKN2A protein]; Chloroquine inhibits the reaction [(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of CDKN2A protein]] 		CTD PMID:34673010 PMID:36792013 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Chat choline O-acetyltransferase multiple interactions
decreases activity 		ISO catalpol inhibits the reaction [Galactose results in decreased activity of CHAT protein] CTD PMID:23612000 NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,657,362...7,717,093 		JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 multiple interactions
decreases expression 		ISO catalpol inhibits the reaction [Galactose results in decreased expression of CHRM1 protein] CTD PMID:23612000 NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases expression 		ISO gentiopicroside analog inhibits the reaction [Galactose results in decreased expression of CTNNB1 protein] CTD PMID:36878094 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cybb cytochrome b-245 beta chain increases expression
multiple interactions 		EXP Galactose results in increased expression of CYBB protein
agomelatine inhibits the reaction [Galactose results in increased expression of CYBB protein]; Melatonin inhibits the reaction [Galactose results in increased expression of CYBB protein] 		CTD PMID:34673010 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression 		ISO
EXP 		[Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of DDIT3 protein]; Phycocyanin inhibits the reaction [Galactose results in increased expression of DDIT3 protein]
agomelatine inhibits the reaction [Galactose results in increased expression of DDIT3 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of DDIT3 protein] 		CTD PMID:23036742 PMID:29427785 PMID:34673010 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dnm1l dynamin 1-like increases expression
multiple interactions 		ISO
EXP 		Galactose results in increased expression of DNM1L protein
MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein] 		CTD PMID:28302704 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation 		EXP agomelatine inhibits the reaction [Galactose results in increased phosphorylation of EIF2AK3 protein]; Melatonin inhibits the reaction [Galactose results in increased phosphorylation of EIF2AK3 protein] CTD PMID:34673010 NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 increases phosphorylation
multiple interactions 		EXP Galactose results in increased phosphorylation of ERN1 protein
agomelatine inhibits the reaction [Galactose results in increased phosphorylation of ERN1 protein] 		CTD PMID:34673010 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions
increases expression 		EXP Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of FGF2 protein] CTD PMID:30367734 NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221 		JBrowse link
G Galk1 galactokinase 1 multiple interactions
increases metabolic processing 		ISO [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate CTD PMID:20696150 NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337 		JBrowse link
G Gap43 growth associated protein 43 decreases expression
multiple interactions 		ISO Galactose results in decreased expression of GAP43 mRNA
Quercetin inhibits the reaction [Galactose results in decreased expression of GAP43 mRNA] 		CTD PMID:16707173 NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions 		EXP Galactose results in decreased expression of GCLC mRNA
Saponins inhibits the reaction [Galactose results in decreased expression of GCLC mRNA] 		CTD PMID:25892055 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions
decreases expression 		EXP candesartan inhibits the reaction [Galactose results in decreased expression of GDNF mRNA] CTD PMID:34906534 NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression 		EXP agomelatine inhibits the reaction [Galactose results in increased expression of GFAP protein]; Melatonin inhibits the reaction [Galactose results in increased expression of GFAP protein] CTD PMID:34673010 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Glb1 galactosidase, beta 1 increases expression
multiple interactions 		ISO Galactose results in increased expression of GLB1 protein
(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of GLB1 protein]; Chloroquine inhibits the reaction [(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of GLB1 protein]] 		CTD PMID:36792013 NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127 		JBrowse link
G Glo1 glyoxalase 1 multiple interactions ISO Galactose results in decreased expression of and results in decreased activity of GLO1 protein; protocatechuic acid inhibits the reaction [Galactose results in decreased expression of and results in decreased activity of GLO1 protein] CTD PMID:22687555 NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO [Lipopolysaccharides co-treated with Galactose] results in increased expression of GPT protein; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of GPT protein] CTD PMID:34416243 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gpx1 glutathione peroxidase 1 multiple interactions
decreases expression 		ISO theaflavin-3,3'-digallate inhibits the reaction [Galactose results in decreased expression of GPX1 mRNA] CTD PMID:36638877 NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024 		JBrowse link
G Gpx4 glutathione peroxidase 4 multiple interactions EXP [Galactose co-treated with Finasteride] results in increased expression of GPX4 protein CTD PMID:39265715 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982 		JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 increases expression
multiple interactions 		EXP Galactose results in increased expression of GRIN1 protein
agomelatine inhibits the reaction [Galactose results in increased expression of GRIN1 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of GRIN1 protein] 		CTD PMID:34673010 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603 		JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B increases expression
multiple interactions 		EXP Galactose results in increased expression of GRIN2B protein
agomelatine inhibits the reaction [Galactose results in increased expression of GRIN2B protein]; Melatonin inhibits the reaction [Galactose results in increased expression of GRIN2B protein] 		CTD PMID:34673010 NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO Galactose results in increased expression of and results in decreased phosphorylation of GSK3B protein; gentiopicroside analog inhibits the reaction [Galactose results in increased expression of and results in decreased phosphorylation of GSK3B protein] CTD PMID:36878094 NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gss glutathione synthetase multiple interactions
decreases expression 		ISO sodium bisulfide inhibits the reaction [Galactose results in decreased expression of GSS mRNA] CTD PMID:23274001 NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198 		JBrowse link
G Hes1 hes family bHLH transcription factor 1 multiple interactions ISO [Galactose co-treated with Aluminum Chloride] results in increased expression of HES1 protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of HES1 protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of HES1 protein] CTD PMID:35537655 NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO Galactose affects the reaction [Fusaric Acid affects the expression of HIF1A protein] CTD PMID:31654802 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression 		EXP
ISO 		Saponins inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA]
albicanol inhibits the reaction [Galactose results in decreased expression of HMOX1 protein]; Lycopene inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA] 		CTD PMID:25892055 PMID:28974442 PMID:33761044 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hsf1 heat shock transcription factor 1 increases activity ISO Galactose results in increased activity of HSF1 protein CTD PMID:34170685 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression 		ISO
EXP 		Phycocyanin inhibits the reaction [Galactose results in increased expression of HSPA5 protein]
Melatonin inhibits the reaction [Galactose results in increased expression of HSPA5 protein] 		CTD PMID:23036742 PMID:34673010 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ifnb1 interferon beta 1 multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein] CTD PMID:23535186 NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:103,020,969...103,021,523 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO [Galactose co-treated with Aluminum Chloride] results in decreased expression of IL10 protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of IL10 protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in decreased expression of IL10 protein] CTD PMID:35537655 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
increases secretion 		ISO
EXP 		Galactose results in increased expression of IL1B mRNA; Galactose results in increased expression of IL1B protein
[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein; albicanol inhibits the reaction [Galactose results in increased expression of IL1B mRNA]; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]; catalpol inhibits the reaction [Galactose results in increased expression of IL1B protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL1B protein]; Lycopene inhibits the reaction [Galactose results in increased expression of IL1B protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL1B protein] 		CTD PMID:22687555 PMID:23612000 PMID:28974442 PMID:29405769 PMID:32295448 More... NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
increases secretion 		ISO
EXP 		[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein; [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactose] results in increased expression of IL6 protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IL6 protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL6 protein]; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of IL6 protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein]
Galactose promotes the reaction [sodium arsenite results in increased expression of IL6 mRNA]
Galactose results in increased expression of IL6 mRNA; Galactose results in increased expression of IL6 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside compound K inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] 		CTD PMID:22687555 PMID:23535186 PMID:29412148 PMID:32295448 PMID:34416243 More... NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ins1 insulin 1 increases expression EXP Galactose results in increased expression of INS1 protein CTD PMID:39265715 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Irf3 interferon regulatory factor 3 multiple interactions ISO
EXP 		[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of IRF3 mRNA; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of IRF3 mRNA] 		CTD PMID:23535186 PMID:29405769 NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935 		JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 multiple interactions
increases expression 		EXP agomelatine inhibits the reaction [Galactose results in increased expression of ITPR3 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of ITPR3 protein] CTD PMID:34673010 NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] affects the localization of and results in increased expression of JUN protein modified form; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of JUN protein modified form] CTD PMID:23535186 NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression
multiple interactions 		ISO Galactose results in increased expression of KEAP1 mRNA; Galactose results in increased expression of KEAP1 protein
albicanol inhibits the reaction [Galactose results in increased expression of KEAP1 mRNA]; albicanol inhibits the reaction [Galactose results in increased expression of KEAP1 protein] 		CTD PMID:33761044 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Lct lactase increases hydrolysis EXP LCT protein results in increased hydrolysis of Galactose CTD PMID:14701853 NCBI chr13:39,781,929...39,824,456
Ensembl chr13:39,781,929...39,824,456 		JBrowse link
G Lrp1 LDL receptor related protein 1 multiple interactions
decreases expression 		ISO [Ethanol co-treated with Galactose] results in decreased expression of LRP1 protein
Galactose results in decreased expression of LRP1 protein 		CTD PMID:33516661 NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910 		JBrowse link
G Lrp6 LDL receptor related protein 6 multiple interactions ISO [Galactose co-treated with gentiopicroside analog] results in increased expression of LRP6 protein CTD PMID:36878094 NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions 		EXP Galactose results in increased phosphorylation of MAPK1 protein
Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased phosphorylation of MAPK1 protein] 		CTD PMID:30367734 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation
multiple interactions 		EXP Galactose results in increased phosphorylation of MAPK3 protein
Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased phosphorylation of MAPK3 protein] 		CTD PMID:30367734 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases expression 		EXP Galactose promotes the reaction [sodium arsenite results in increased expression of MAPK8 mRNA]
Galactose results in increased expression of MAPK8 mRNA 		CTD PMID:35259467 NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapt microtubule-associated protein tau increases expression
multiple interactions 		ISO Galactose results in increased expression of MAPT protein
gentiopicroside analog inhibits the reaction [Galactose results in increased expression of MAPT protein] 		CTD PMID:36878094 NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Mfn2 mitofusin 2 increases expression
multiple interactions 		EXP
ISO 		Galactose results in increased expression of MFN2 protein
MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein] 		CTD PMID:28302704 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mir34a microRNA 34a increases expression
multiple interactions 		EXP
ISO 		Galactose results in increased expression of MIR34A mRNA
MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] 		CTD PMID:28302704 NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions
increases activity 		EXP Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased activity of MMP2 protein] CTD PMID:30367734 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression 		EXP agomelatine inhibits the reaction [Galactose results in decreased expression of MMP9 protein]; Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of and results in increased activity of MMP9 protein]; Galactose results in increased expression of and results in increased activity of MMP9 protein; Melatonin inhibits the reaction [Galactose results in decreased expression of MMP9 protein] CTD PMID:30367734 PMID:34673010 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mt-co1 mitochondrially encoded cytochrome c oxidase I multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein CTD PMID:25997894 NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867 		JBrowse link
G Mt-nd4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 affects metabolic processing ISO ND4 protein affects the metabolism of Galactose CTD PMID:8662757 NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537 		JBrowse link
G Mt-nd6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 affects metabolic processing ISO ND6 protein affects the metabolism of Galactose CTD PMID:9707444 NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO
EXP 		[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of MYD88 mRNA; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of MYD88 mRNA] 		CTD PMID:23535186 PMID:29405769 NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:119,074,437...119,079,415 		JBrowse link
G Ndufb8 NADH:ubiquinone oxidoreductase subunit B8 multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein CTD PMID:25997894 NCBI chr 1:243,408,656...243,413,715
Ensembl chr 1:243,408,619...243,413,817 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects localization
multiple interactions
decreases expression 		EXP
ISO 		Galactose affects the localization of NFE2L2 protein
albicanol inhibits the reaction [Galactose results in decreased expression of NFE2L2 mRNA]; albicanol inhibits the reaction [Galactose results in decreased expression of NFE2L2 protein]; theaflavin-3,3'-digallate inhibits the reaction [Galactose results in decreased expression of NFE2L2 mRNA]
Galactose results in decreased expression of NFE2L2 mRNA; Galactose results in decreased expression of NFE2L2 protein
Saponins inhibits the reaction [Galactose affects the localization of NFE2L2 protein] 		CTD PMID:25892055 PMID:33761044 PMID:36638877 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases expression
multiple interactions 		ISO
EXP 		Galactose results in increased expression of NFKB1 mRNA; Galactose results in increased expression of NFKB1 protein
Galactose promotes the reaction [sodium arsenite results in increased expression of NFKB1 mRNA] 		CTD PMID:22687555 PMID:35259467 NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression
increases activity 		ISO Oligopeptides inhibits the reaction [Galactose results in increased activity of NOS2 protein]
Galactose results in increased expression of NOS2 mRNA 		CTD PMID:23796539 PMID:28974442 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Notch1 notch receptor 1 multiple interactions ISO [Galactose co-treated with Aluminum Chloride] results in increased expression of NOTCH1 protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of NOTCH1 protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of NOTCH1 protein] CTD PMID:35537655 NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531 		JBrowse link
G Nox4 NADPH oxidase 4 increases expression
multiple interactions 		EXP Galactose results in increased expression of NOX4 protein
agomelatine inhibits the reaction [Galactose results in increased expression of NOX4 protein]; Melatonin inhibits the reaction [Galactose results in increased expression of NOX4 protein] 		CTD PMID:34673010 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
decreases expression 		EXP
ISO 		Saponins inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA]
albicanol inhibits the reaction [Galactose results in decreased expression of NQO1 protein]; Lycopene inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA] 		CTD PMID:25892055 PMID:28974442 PMID:33761044 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Oat ornithine aminotransferase multiple interactions EXP Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] CTD PMID:2827574 NCBI chr 1:196,777,973...196,797,754
Ensembl chr 1:187,347,865...187,367,682 		JBrowse link
G Ocln occludin decreases expression ISO Galactose results in decreased expression of OCLN protein CTD PMID:33516661 NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150 		JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO Galactose affects the reaction [Fusaric Acid results in increased expression of PDK1 protein] CTD PMID:31654802 NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038 		JBrowse link
G Pkm pyruvate kinase M1/2 multiple interactions ISO Galactose affects the reaction [Fusaric Acid results in increased expression of PKM mRNA] CTD PMID:31654802 NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599 		JBrowse link
G Plau plasminogen activator, urokinase increases expression
multiple interactions 		EXP Galactose results in increased expression of PLAU protein
Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of PLAU protein] 		CTD PMID:30367734 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression EXP Galactose results in decreased expression of PPARGC1A protein CTD PMID:28302704 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Prdx2 peroxiredoxin 2 multiple interactions
decreases expression 		ISO theaflavin-3,3'-digallate inhibits the reaction [Galactose results in decreased expression of PRDX2 mRNA] CTD PMID:36638877 NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194 		JBrowse link
G Psenen presenilin enhancer gamma secretase subunit multiple interactions
increases expression 		ISO gentiopicroside analog inhibits the reaction [Galactose results in increased expression of PSENEN protein] CTD PMID:36878094 NCBI chr 1:85,814,905...85,816,654
Ensembl chr 1:85,814,905...85,816,192 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression 		ISO Galactose results in increased expression of and results in increased activity of PTGS2 protein; lycopene inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 protein] CTD PMID:22687555 PMID:28974442 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rbpj recombination signal binding protein for immunoglobulin kappa J region multiple interactions ISO [Galactose co-treated with Aluminum Chloride] results in increased expression of RBPJ protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of RBPJ protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of RBPJ protein] CTD PMID:35537655 NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
affects localization
increases expression 		ISO [Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein; [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of and results in increased phosphorylation of RELA protein]; Galactose results in increased expression of and results in increased activity of RELA protein; protocatechuic acid inhibits the reaction [Galactose results in increased expression of and results in increased activity of RELA protein]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein]
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein]
Galactose results in increased expression of RELA mRNA; Galactose results in increased expression of RELA protein 		CTD PMID:22687555 PMID:23535186 PMID:29412148 PMID:35537655 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rest RE1-silencing transcription factor multiple interactions
decreases expression 		ISO gentiopicroside analog inhibits the reaction [Galactose results in decreased expression of REST protein] CTD PMID:36878094 NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354 		JBrowse link
G Rnf31 ring finger protein 31 multiple interactions ISO [Lipopolysaccharides co-treated with Galactose] results in increased expression of RNF31 protein; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of GPT protein]; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of IL6 protein]; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of TNF protein]; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of TNFAIP3 protein] CTD PMID:34416243 NCBI chr15:33,053,450...33,065,285
Ensembl chr15:29,083,631...29,101,915 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression 		EXP
ISO 		Saponins inhibits the reaction [Galactose results in decreased expression of SIRT1 protein]
[Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [resveratrol results in increased expression of SIRT1 protein] 		CTD PMID:25892055 PMID:27358235 PMID:29426000 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases transport ISO SLC2A2 protein results in increased transport of Galactose CTD PMID:8457197 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 increases transport
multiple interactions 		ISO SLC2A3 protein results in increased transport of Galactose
Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose] 		CTD PMID:8457197 NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472 		JBrowse link
G Slc5a1 solute carrier family 5 member 1 multiple interactions
affects transport 		ISO Galactose inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside]
SLC5A1 protein affects the transport of Galactose 		CTD PMID:16300400 PMID:17288452 NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression 		ISO
EXP 		theaflavin-3,3'-digallate inhibits the reaction [Galactose results in decreased expression of SOD1 mRNA]
[Galactose co-treated with Finasteride] results in increased expression of SOD1 mRNA 		CTD PMID:36638877 PMID:39265715 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 decreases expression
multiple interactions 		EXP
ISO 		Galactose results in decreased expression of SOD2 mRNA
albicanol inhibits the reaction [Galactose results in decreased expression of SOD2 protein]
Saponins inhibits the reaction [Galactose results in decreased expression of SOD2 mRNA] 		CTD PMID:25892055 PMID:33761044 NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sord sorbitol dehydrogenase increases expression ISO Galactose results in increased expression of SORD mRNA CTD PMID:22687555 NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions
increases expression 		EXP Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of SP1 protein] CTD PMID:30367734 NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
increases expression 		ISO
EXP 		Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]]; Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein]
(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [(1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]] 		CTD PMID:28302704 PMID:29426000 PMID:36792013 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 increases expression ISO Galactose results in increased expression of SREBF1 mRNA CTD PMID:10913129 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Tfam transcription factor A, mitochondrial multiple interactions EXP [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein CTD PMID:25997894 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292 		JBrowse link
G Tfeb transcription factor EB multiple interactions
affects localization 		ISO (1E,4E)-1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one inhibits the reaction [Galactose affects the localization of TFEB protein] CTD PMID:36792013 NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
increases expression 		EXP Alpinia oxyphylla fruit extract inhibits the reaction [Galactose results in increased expression of TGFB1 protein] CTD PMID:30367734 NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Ticam1 TIR domain containing adaptor molecule 1 multiple interactions ISO
EXP 		[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of TICAM1 mRNA; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TICAM1 mRNA] 		CTD PMID:23535186 PMID:29405769 NCBI chr 9:1,102,559...1,111,023
Ensembl chr 9:1,102,366...1,123,147 		JBrowse link
G Tjp1 tight junction protein 1 decreases expression
multiple interactions 		ISO Galactose results in decreased expression of TJP1 protein
Ethanol promotes the reaction [Galactose results in decreased expression of TJP1 protein] 		CTD PMID:33516661 NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432 		JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions EXP [Galactose co-treated with Aluminum Chloride] results in increased expression of TLR2 mRNA; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TLR2 mRNA] CTD PMID:29405769 NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:169,197,419...169,206,630 		JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions ISO
EXP 		[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of TLR4 mRNA; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TLR4 mRNA] 		CTD PMID:23535186 PMID:29405769 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases secretion 		ISO
EXP 		[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein; [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactose] results in increased expression of TNF protein; albicanol inhibits the reaction [Galactose results in increased expression of TNF mRNA]; astragalin inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]; catalpol inhibits the reaction [Galactose results in increased expression of TNF protein]; Estradiol inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]; Lycopene inhibits the reaction [Galactose results in increased expression of TNF protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of TNF protein]; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of TNF protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]
[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein; candesartan inhibits the reaction [Galactose results in increased expression of TNF mRNA]; Galactose promotes the reaction [sodium arsenite results in increased expression of TNF mRNA]; thymoquinone inhibits the reaction [[Galactose co-treated with Aluminum Chloride] results in increased expression of TNF protein]
Galactose results in increased expression of TNF mRNA; Galactose results in increased expression of TNF protein 		CTD PMID:22687555 PMID:23535186 PMID:23612000 PMID:28974442 PMID:29405769 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO [Lipopolysaccharides co-treated with Galactose] results in increased expression of TNFAIP3 protein; RNF31 protein affects the reaction [[Lipopolysaccharides co-treated with Galactose] results in increased expression of TNFAIP3 protein] CTD PMID:34416243 NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:13,709,206...13,725,282 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression 		ISO
EXP 		Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein]
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Finasteride inhibits the reaction [Galactose results in increased expression of TP53 protein] 		CTD PMID:23036742 PMID:25997894 PMID:29426000 PMID:39265715 NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Txnip thioredoxin interacting protein multiple interactions
increases expression 		ISO Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein]]; Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein] CTD PMID:29426000 NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:184,092,991...184,096,886 		JBrowse link
G Txnrd1 thioredoxin reductase 1 decreases expression
multiple interactions 		ISO Galactose results in decreased expression of TXNRD1 mRNA
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of TXNRD1 mRNA] 		CTD PMID:23274001 NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
alpha-D-galactose 1-phosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Galk1 galactokinase 1 multiple interactions ISO [Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate CTD PMID:20696150 NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337 		JBrowse link
kaempferol 3-O-beta-D-galactoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Pla2g2a phospholipase A2 group IIA affects activity ISO kaempferol-3-O-galactoside affects the activity of PLA2G2A protein CTD PMID:8190018 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014 		JBrowse link
quercetin 3-O-beta-D-galactopyranoside term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase increases expression
multiple interactions 		EXP hyperoside results in increased expression of ACHE mRNA
hyperoside results in increased expression of and results in increased activity of ACHE protein 		CTD PMID:27019979 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased cleavage of ATF6 protein] CTD PMID:38848825 NCBI chr13:85,460,312...85,639,959
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO
EXP 		hyperoside inhibits the reaction [Particulate Matter results in increased expression of BAX protein]; hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of BAX protein]
hyperoside inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] 		CTD PMID:18552516 PMID:31326407 PMID:38848825 NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] CTD PMID:31326407 NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of BCL2L11 protein] CTD PMID:38848825 NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 protein CTD PMID:24173369 NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased cleavage of CASP3 protein CTD PMID:24173369 PMID:25354548 NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cat catalase multiple interactions EXP cyclopamine inhibits the reaction [hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]]; hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] CTD PMID:31326407 NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in decreased expression of CCND1 protein] CTD PMID:38848825 NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in decreased expression of CCNE1 protein] CTD PMID:38848825 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in decreased expression of CDK2 protein] CTD PMID:38848825 NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in decreased expression of CDK4 protein] CTD PMID:38848825 NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of CDKN1A protein] CTD PMID:38848825 NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of CDKN2A protein] CTD PMID:38848825 NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of CYCS protein] CTD PMID:18552516 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity
multiple interactions 		ISO hyperoside results in decreased activity of CYP2E1 protein
hyperoside inhibits the reaction [Acetaminophen results in decreased activity of CYP2E1 protein] 		CTD PMID:26772156 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of DDIT3 protein] CTD PMID:38848825 NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased phosphorylation of EIF2AK3 protein] CTD PMID:38848825 NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased phosphorylation of EIF2S1 protein] CTD PMID:38848825 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased phosphorylation of ERN1 protein] CTD PMID:38848825 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO hyperoside inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:22613215 NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions
increases expression 		EXP hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 protein]
hyperoside results in increased expression of GLI1 mRNA; hyperoside results in increased expression of GLI1 protein 		CTD PMID:31326407 NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:63,156,926...63,169,251 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO hyperoside inhibits the reaction [Acetaminophen results in increased activity of GPT protein] CTD PMID:26772156 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of HSPA5 protein] CTD PMID:38848825 NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] CTD PMID:30125551 NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:30125551 NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in decreased expression of MCL1 protein] CTD PMID:38848825 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mir21 microRNA 21 multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of MIR21 mRNA; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein]; MIR21 mRNA results in decreased susceptibility to [Quercetin co-treated with hyperoside] CTD PMID:25354548 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348 		JBrowse link
G Mir27a microRNA 27a multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of MIR27A mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] CTD PMID:24173369 NCBI chr19:23,954,831...23,954,917
Ensembl chr19:23,954,831...23,954,917 		JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of MMP1 protein] CTD PMID:38848825 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO hyperoside inhibits the reaction [Particulate Matter results in increased expression of MMP9 protein] CTD PMID:38848825 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 affects localization ISO hyperoside affects the localization of NFE2L2 protein CTD PMID:26772156 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] CTD PMID:30125551 NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression EXP Hyperoside increases expression of Nqo1 protein in liver RGD PMID:31399183 RGD:25823190 NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased cleavage of PARP1 protein CTD PMID:24173369 PMID:25354548 NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdcd4 programmed cell death 4 multiple interactions ISO [Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA; [Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein] CTD PMID:25354548 NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275 		JBrowse link
G Prima1 proline rich membrane anchor 1 increases expression EXP hyperoside results in increased expression of PRIMA1 mRNA CTD PMID:27019979 NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] CTD PMID:30125551 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Shh sonic hedgehog signaling molecule increases expression
multiple interactions 		EXP hyperoside results in increased expression of SHH mRNA; hyperoside results in increased expression of SHH protein
hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH protein] 		CTD PMID:31326407 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions ISO hyperoside inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of SIRT1 protein] CTD PMID:18552516 NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO hyperoside analog results in increased expression of SLC2A2 mRNA CTD PMID:33493636 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933 		JBrowse link
G Slc5a1 solute carrier family 5 member 1 increases expression ISO hyperoside analog results in increased expression of SLC5A1 mRNA CTD PMID:33493636 NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547 		JBrowse link
G Smo smoothened, frizzled class receptor increases expression
multiple interactions 		EXP hyperoside results in increased expression of SMO mRNA; hyperoside results in increased expression of SMO protein
hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO protein] 		CTD PMID:31326407 NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829 		JBrowse link
G Sp1 Sp1 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 protein CTD PMID:24173369 NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:133,541,491...133,571,961 		JBrowse link
G Sp3 Sp3 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of SP3 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP3 protein CTD PMID:24173369 NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342 		JBrowse link
G Sp4 Sp4 transcription factor multiple interactions ISO [Quercetin co-treated with hyperoside] results in decreased expression of SP4 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP4 protein CTD PMID:24173369 NCBI chr 6:139,187,458...139,252,741
Ensembl chr 6:139,192,147...139,252,126 		JBrowse link
G Sult2a1 sulfotransferase family 2A member 1 multiple interactions
increases expression 		ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of SULT2A1 mRNA]
hyperoside results in increased expression of SULT2A1 mRNA 		CTD PMID:26772156 NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] CTD PMID:30125551 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein] CTD PMID:30125551 NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591 		JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 multiple interactions
increases expression 		ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A1 mRNA]
hyperoside results in increased expression of UGT1A1 mRNA 		CTD PMID:26772156 NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt1a6 UDP glucuronosyltransferase family 1 member A6 multiple interactions ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A6 mRNA] CTD PMID:26772156 NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465 		JBrowse link
G Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 multiple interactions
increases expression 		ISO hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT2B1 mRNA]
hyperoside results in increased expression of UGT2B1 mRNA 		CTD PMID:26772156 NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] CTD PMID:30125551 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
G Zbtb10 zinc finger and BTB domain containing 10 multiple interactions ISO [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] CTD PMID:24173369 NCBI chr 2:92,475,254...92,509,892
Ensembl chr 2:92,479,014...92,512,515 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 20845
    role 20805
      biological role 20803
        biochemical role 20250
          metabolite 20231
            fundamental metabolite 14711
              galactose 229
                D-galactose 229
                  D-galactopyranose 229
                    1-(D-glucopyranosyloxy)-3-hydroxypropan-2-yl D-galactopyranoside 0
                    1-O-(N-benzyloxycarbonylaminoethyl)-3-O-benzoyl-alpha-anthroside 0
                    2-amino-2-deoxy-D-galactopyranose + 111
                    2-aminoethyl 4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-alpha-D-glucoside 0
                    2-deoxy-2-fluoro-D-galactopyranose + 0
                    3,4-O-[(1S)-1-carboxyethylidene]-beta-D-galactose 0
                    4,6-O-[(1R)-1-carboxyethylidene]-D-galactose + 0
                    4-acetamido-4,6-dideoxy-D-galactose + 0
                    6-O-(trans-feruloyl)-D-galactopyranose 0
                    D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Glcp 0
                    D-Galp-(1->4)-D-GlcpNAc + 0
                    D-Glcp-(1->2)-D-Galp 0
                    D-galactose 4-sulfate 0
                    D-galactose 6-sulfate + 0
                    N-benzyloxycarbonylaminoethyl-4-azido-3-O-benzoyl-2-O-methyl-4,6-dideoxy-alpha-D-glucopyranoside 0
                    alpha-D-Galf-(1->2)-D-Galp + 0
                    alpha-D-GalpNAc-(1->6)-D-Galp 0
                    alpha-D-Glcp-(1->2)-D-Galp 0
                    alpha-D-Glcp-(1->3)-D-Galp + 0
                    alpha-D-Manp-(1->2)-D-Galp + 0
                    alpha-D-Manp-(1->4)-D-Galp 0
                    alpha-D-Manp-(1->6)-D-Galp + 0
                    alpha-D-galactose + 121
                    alpha-L-Fucp-(1->3)-D-Galp + 0
                    alpha-L-Fucp-(1->4)-D-Galp 0
                    alpha-L-Fucp-(1->6)-D-Galp + 0
                    beta-D-Galf-(1->3)-D-Galp + 0
                    beta-D-Galp-(1->2)-D-Galp 0
                    beta-D-GalpNAc-(1->6)-D-Galp 0
                    beta-D-Glcp-(1->3)-D-Galp + 0
                    beta-D-GlcpNAc-(1->3)-D-Galp + 0
                    beta-D-GlcpNAc-(1->6)-D-Galp + 0
                    beta-D-Manp-(1->4)-D-Galp + 0
                    beta-D-galactopyranosyl D-galactopyranoside 0
                    beta-D-galactose + 57
                    beta-L-Fucp-(1->2)-D-Galp + 0
                    beta-L-Fucp-(1->3)-D-Galp + 0
                    beta-L-Fucp-(1->4)-D-Galp + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 20845
    subatomic particle 20843
      composite particle 20843
        hadron 20843
          baryon 20843
            nucleon 20843
              atomic nucleus 20843
                atom 20843
                  main group element atom 20766
                    p-block element atom 20766
                      carbon group element atom 20699
                        carbon atom 20693
                          organic molecular entity 20693
                            heteroorganic entity 20202
                              organochalcogen compound 19890
                                organooxygen compound 19792
                                  carbohydrates and carbohydrate derivatives 15420
                                    carbohydrate 15420
                                      monosaccharide 4896
                                        aldose 3245
                                          aldohexose 2898
                                            D-aldohexose 2888
                                              D-galactose 229
                                                D-galactopyranose 229
                                                  1-(D-glucopyranosyloxy)-3-hydroxypropan-2-yl D-galactopyranoside 0
                                                  1-O-(N-benzyloxycarbonylaminoethyl)-3-O-benzoyl-alpha-anthroside 0
                                                  2-amino-2-deoxy-D-galactopyranose + 111
                                                  2-aminoethyl 4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-alpha-D-glucoside 0
                                                  2-deoxy-2-fluoro-D-galactopyranose + 0
                                                  3,4-O-[(1S)-1-carboxyethylidene]-beta-D-galactose 0
                                                  4,6-O-[(1R)-1-carboxyethylidene]-D-galactose + 0
                                                  4-acetamido-4,6-dideoxy-D-galactose + 0
                                                  6-O-(trans-feruloyl)-D-galactopyranose 0
                                                  D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Glcp 0
                                                  D-Galp-(1->4)-D-GlcpNAc + 0
                                                  D-Glcp-(1->2)-D-Galp 0
                                                  D-galactose 4-sulfate 0
                                                  D-galactose 6-sulfate + 0
                                                  N-benzyloxycarbonylaminoethyl-4-azido-3-O-benzoyl-2-O-methyl-4,6-dideoxy-alpha-D-glucopyranoside 0
                                                  alpha-D-Galf-(1->2)-D-Galp + 0
                                                  alpha-D-GalpNAc-(1->6)-D-Galp 0
                                                  alpha-D-Glcp-(1->2)-D-Galp 0
                                                  alpha-D-Glcp-(1->3)-D-Galp + 0
                                                  alpha-D-Manp-(1->2)-D-Galp + 0
                                                  alpha-D-Manp-(1->4)-D-Galp 0
                                                  alpha-D-Manp-(1->6)-D-Galp + 0
                                                  alpha-D-galactose + 121
                                                  alpha-L-Fucp-(1->3)-D-Galp + 0
                                                  alpha-L-Fucp-(1->4)-D-Galp 0
                                                  alpha-L-Fucp-(1->6)-D-Galp + 0
                                                  beta-D-Galf-(1->3)-D-Galp + 0
                                                  beta-D-Galp-(1->2)-D-Galp 0
                                                  beta-D-GalpNAc-(1->6)-D-Galp 0
                                                  beta-D-Glcp-(1->3)-D-Galp + 0
                                                  beta-D-GlcpNAc-(1->3)-D-Galp + 0
                                                  beta-D-GlcpNAc-(1->6)-D-Galp + 0
                                                  beta-D-Manp-(1->4)-D-Galp + 0
                                                  beta-D-galactopyranosyl D-galactopyranoside 0
                                                  beta-D-galactose + 57
                                                  beta-L-Fucp-(1->2)-D-Galp + 0
                                                  beta-L-Fucp-(1->3)-D-Galp + 0
                                                  beta-L-Fucp-(1->4)-D-Galp + 0
paths to the root